AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Omnicell Inc

Healthcare US OMCL


Last update at 2024-02-22T20:50:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2.45300M 66.01M 29.35M 73.93M 35.62M
Minority interest - - - - -
Net income 5.65M 77.85M 32.19M 61.34M 37.73M
Selling general administrative 486.34M 389.43M 307.61M 289.92M 263.10M
Selling and marketing expenses - - - - -
Gross profit 588.99M 554.65M 413.29M 436.91M 372.33M
Reconciled depreciation 99.17M 84.93M 71.59M 64.12M 51.35M
Ebit -2.32300M 89.51M 35.53M 78.35M 44.39M
Ebitda 96.85M 174.44M 107.12M 142.47M 95.74M
Depreciation and amortization 99.17M 84.93M 71.59M 64.12M 51.35M
Non operating income net other -0.13000M -23.50000M -6.17700M -4.41900M -8.77600M
Operating income -2.32300M 89.51M 35.53M 78.35M 44.39M
Other operating expenses 1298.27M 1042.51M 856.68M 818.67M 742.92M
Interest expense 0.13M -23.50000M -6.17700M -4.41900M 8.78M
Tax provision -8.10100M -11.84200M -2.84500M 12.60M -2.11300M
Interest income - - - 4.42M 8.78M
Net interest income -0.13000M -23.50000M -6.17700M -4.41900M -8.77600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -8.10100M -11.84200M -2.84500M 12.60M -2.11300M
Total revenue 1295.95M 1132.02M 892.21M 897.03M 787.31M
Total operating expenses 591.31M 465.15M 377.77M 358.56M 327.94M
Cost of revenue 706.96M 577.37M 478.92M 460.12M 414.98M
Total other income expense net -0.13000M -23.50000M -6.17700M -4.41900M -8.77600M
Discontinued operations - - - - -
Net income from continuing ops 5.65M 77.85M 32.19M 61.34M 37.73M
Net income applicable to common shares 5.65M 77.85M 32.19M 61.34M 37.73M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2210.76M 2142.50M 1824.50M 1240.81M 1081.24M
Intangible assets 242.91M 277.62M 168.21M 124.87M 143.69M
Earning assets - - - - -
Other current assets 77.36M 48.33M 41.04M 15.18M 12.14M
Total liab 1080.62M 995.81M 857.00M 395.56M 401.62M
Total stockholder equity 1130.14M 1146.69M 967.50M 845.25M 679.62M
Deferred long term liab 2.10M 51.70M 4.25M 39.09M 41.48M
Other current liab 235.35M 204.30M 123.86M 89.66M 75.71M
Common stock 0.06M 0.05M 0.05M 0.05M 0.05M
Capital stock 0.06M 0.05M 0.05M 0.05M 0.05M
Retained earnings 390.73M 368.57M 290.72M 258.79M 197.45M
Other liab 46.20M 79.74M 64.48M 57.89M 61.63M
Good will 734.27M 738.90M 499.31M 336.54M 335.89M
Other assets 138.99M 225.59M 268.50M 100.72M 96.22M
Cash 330.36M 349.05M 485.93M 127.21M 67.19M
Cash and equivalents - - - - -
Total current liabilities 428.45M 876.16M 276.42M 237.00M 204.58M
Current deferred revenue 118.95M 112.20M 100.05M 90.89M 81.83M
Net debt 286.38M 179.01M 30.17M -26.54100M 68.22M
Short term debt 10.76M 488.15M 12.20M 10.06M 8.99M
Short long term debt - 488.15M - - -
Short long term debt total 616.74M 528.06M 516.10M 100.67M 135.42M
Other stockholder equity 756.44M 786.47M 682.25M 595.86M 492.97M
Property plant equipment 93.96M 119.69M 59.07M 54.25M 51.50M
Total current assets 881.81M 780.70M 829.41M 483.24M 397.13M
Long term investments 32.92M 18.39M 22.16M 19.75M 17.08M
Net tangible assets 152.96M 130.17M 967.50M 845.25M 200.04M
Short term investments 11.49M 10.66M 10.25M - -
Net receivables 299.47M 240.89M 190.12M 218.36M 196.24M
Long term debt 566.57M - 467.20M 50.00M 135.42M
Inventory 147.55M 119.92M 96.30M 108.01M 100.87M
Accounts payable 63.39M 71.51M 40.31M 46.38M 38.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -17.08700M -8.40700M -5.52200M -9.44600M -10.85400M
Additional paid in capital - - - - -
Common stock total equity 0.06M 0.05M 0.05M 0.05M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity 390.73M 368.57M 290.72M 258.79M 197.45M
Treasury stock -290.31900M -238.10900M -238.10900M -185.07400M -185.07400M
Accumulated amortization - - - - -
Non currrent assets other 164.50M 191.31M 176.21M 151.90M 120.76M
Deferred long term asset charges - - - - -
Non current assets total 1328.95M 1361.79M 995.09M 757.57M 684.11M
Capital lease obligations 50.17M 39.91M 48.90M 60.73M -
Long term debt total 566.57M - 467.20M 50.00M 135.42M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -58.66900M -412.49800M -279.86600M -61.66400M -54.37400M
Change to liabilities 10.64M 53.26M 17.12M 19.44M 11.82M
Total cashflows from investing activities -58.66900M -412.49800M -279.86600M -61.66400M -54.37400M
Net borrowings - - 408.49M -92.32100M -77.00000M
Total cash from financing activities -20.95300M 47.36M 456.27M -23.47900M -13.59700M
Change to operating activities 0.29M 10.06M -13.22100M 0.52M 8.37M
Net income 5.65M 77.85M 32.19M 61.34M 37.73M
Change in cash -2.78500M -134.30000M 362.71M 60.02M 34.77M
Begin period cash flow 355.62M 489.92M 127.21M 67.19M 32.42M
End period cash flow 352.83M 355.62M 489.92M 127.21M 67.19M
Total cash from operating activities 77.78M 231.81M 185.87M 145.01M 103.97M
Issuance of capital stock - 0.00000M 0.00000M 37.81M 39.57M
Depreciation 99.17M 84.93M 71.59M 64.12M 51.35M
Other cashflows from investing activities -11.13300M -383.53100M -257.02400M -45.77000M -30.67700M
Dividends paid - - - - -
Change to inventory -30.11500M -25.69500M 12.36M -8.12300M -6.76300M
Change to account receivables -60.35700M -43.22000M 12.03M -23.52000M -6.19200M
Sale purchase of stock -52.21000M 67.35M -53.03500M 78.51M 70.18M
Other cashflows from financing activities 31.26M 47.36M 709.30M 28.71M 23.84M
Change to netincome 31.61M 50.32M 38.42M 33.16M 23.31M
Capital expenditures 60.74M 58.34M 54.87M 61.66M 54.37M
Change receivables -75.71100M -37.62700M 33.96M -25.23900M -7.87200M
Cash flows other operating 44.61M 10.61M -15.61600M 8.68M -7.90600M
Exchange rate changes - -0.97400M 0.44M 0.15M -1.22700M
Cash and cash equivalents changes -1.84100M -134.30000M 362.71M 60.02M 34.77M
Change in working capital -73.46600M -3.34000M 37.30M -15.81000M -10.71800M
Stock based compensation 68.25M 53.16M 44.70M 34.05M 28.89M
Other non cash items 15.50M 22.48M 6.63M 2.65M 2.42M
Free cash flow 17.04M 173.47M 131.00M 83.34M 49.59M


  • Previous Close 27.29
  • Market Cap1783.31M
  • Volume431070
  • P/E Ratio-
  • Dividend Yield7.04%
  • EBITDA18.18M
  • Revenue TTM1185.94M
  • Revenue Per Share TTM26.35
  • Gross Profit TTM 596.71M
  • Diluted EPS TTM-0.77

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Omnicell Inc
-1.0 3.66% 26.29 0.0 29.50 1.50 1.45 1.58 40.32
GE HealthCare Technologies Inc.
2.80 3.29% 87.78 22.39 17.33 1.78 4.79 2.18 11.79
Veeva Systems Inc Class A
5.46 2.52% 221.82 54.61 33.22 12.83 6.73 11.14 58.84
M3 Inc
0.0 0.0% 17.65 29.72 25.00 0.05 4.38 0.04 0.12
M3 Inc
-0.06 0.88% 6.75 31.84 26.25 0.05 4.60 0.04 0.12

Reports Covered

Stock Research & News


Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

Omnicell Inc

590 East Middlefield Road, Mountain View, CA, United States, 94043

Key Executives

Name Title Year Born
Mr. Randall A. Lipps Founder, Exec. Chairman, Pres & CEO 1957
Mr. Peter J. Kuipers Exec. VP & CFO 1972
Ms. Christine Mellon Exec. VP, Chief Admin. & People Officer 1963
Mr. Scott Peter Seidelmann Exec. VP & Chief Commercial Officer 1976
Mr. Joseph Brian Spears Sr. VP, Chief Accounting Officer & Corp. Controller 1960
Mr. Giri Chodavarapu Sr. VP & Chief Information Officer NA
Ms. Kathleen Nemeth Sr. VP of Investor Relations NA
Mr. Corey J. Manley Sr. VP & Chief Legal Officer NA
Ms. Roxanne Turner Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer NA
Mr. Jorge R. Taborga Exec. VP of Engineering & Integration Management Officer 1959

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).